Latest Breaking News On - Sparingvision the company - Page 1 : comparemela.com

SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa

SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

France generalUnited statesAmber fennellNathalie trepoDavide salviNamrata taakParis vision instituteSparingvision the companyFoundation fighting blindnessVision reaches final dose escalation stepData safety monitoring boardChief executive officerInvestigational new drugRetinitis pigmentosaIntellia therapeuticsAdvent france biotechnology

SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phase I/II Gene Therapy Trial

SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phase I/II Gene Therapy Trial
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

France generalUnited statesAmber fennellAvril dalyDavide salviNamrata taakNathalie trepoJoseph martelUniversity of pittsburgh medical centerConsilium strategic communicationsNational hospitalEye centerParis vision instituteRd fundRetina internationalSparingvision the company

SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics

SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

France generalDeniz dalkaraAmber fennellDavide salviNathalie trepoGenevieve wilsonSparingvision the companyRd fundConsilium strategic communicationsTenpoint therapeuticsAdbio partnersOlivier goureau phdInstitut de la visionChief executive officerRetinitis pigmentosaIntellia therapeutics

SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases

SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalComunidad autonoma de catalunaAmber fennellSabine dandiguianGenevieve wilsonIntellia therapeuticsandBpifrance bpifrancepresseDavide salviJeanne cunicelliNathalie trepoFoundation fighting blindnessestablishedFoundation fighting blindnessParis vision instituteSparingvision the companyRd fund

SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases

SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesFrance generalComunidad autonoma de catalunaAmber fennellSabine dandiguianGenevieve wilsonIntellia therapeuticsandKostenloser wertpapierhandelBpifrance bpifrancepresseDavide salviJeanne cunicelliNathalie trepoRetinal degeneration fund rdFoundation fighting blindnessParis vision instituteSparingvision the company